Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2345MR)

This product GTTS-WQ2345MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2345MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14459MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ3810MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ8478MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ5354MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ4175MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ12914MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ11982MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW